MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, today announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc (LSE: RB), has received approval from the U.S. Food and Drug Administration (FDA) to market Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the treatment of opioid dependence. This is the second U.S… (Source: Health News from Medical News Today)
MonoSol Rx Announces Reckitt Benckiser FDA Approval Of Suboxone® Sublingual Film For Treatment Of Opioid Dependence
Previous post: Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases.
